Replies to post #264278 on Innovation Pharmaceuticals Inc (IPIX)

[1oldprof]

Brilacidin is brilacidin. If you modify it, it is not brilacidin anymore. That said, utilizing the artificial polymeric backbone of B, it could be modified to address different applications, which is part of what the UPenn folks did, as long as the biochemical pathways are worked out and the stereochemical relationships between receptor and ligand are known. Knowing these relationships would make it a much more refined process and not as much hit and miss. Absolutely last post here. I know what I have and liking it

[frrol]

The HDP-Ms developed by UoP are all based on arylamide backbones; they differ by the residues hanging off of it. Brilacidin showed the most promise, likely after screening assays. We relinquished our rights to other promising ones, to cut costs. UoP has the highly specialized research faculty and facilities for that development work, it's not something we could do even if we wanted to. Our limited capabilities are to license and clinically test them, and partner with pharmas to commercialize them. Completely different part of the development cycle.

Hopefully, with some capital in our pocket eventually, we can license some back.

[farrell90]

Pete, it is a good question. A better answer to your question can be found by looking at the Brilacidin patents.The other answers are correct, but Brilacidin can be modified chemically to produce different compounds with the possibility of producing different biologic effects and still be considered patent protected property of IPIX.

I am not a biochemist and rarely reads patents, but the Brilacidin patents are written broadly with thousands of possible variations included and protected in the patent.

I have no knowledge on how thoroughly the various compounds have been screened for study, but the volume of the possible combinations means to me that it would be impossible to thoroughly study each compound for all of its possible effects.

The reason to seek patent protection is to give the company the right to defend its invention and that includes close variations in chemical structure.

GLTA Farrell

I look forward to seeing responses from others with more experience

Abstract:
The present invention provides methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.

FIELD OF THE INVENTION

The present invention is directed, in part, to methods of treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&p=1&S1=%22innovation+pharmaceuticals%22&OS=%22innovation+pharmaceuticals%22&RS=%22innovation+pharmaceuticals%22

Unfortunately the patent pages are not labeled, but the next section describes what are called claims of the invention.

Under the next section called summary of invention you will see
548 variations {STR00001 to STR00548} which are described each with a variety of possible chemical substitutions to produce different variations of the base compounds.

I did not try to calculate all the possibilities but my guess is it must be tens of thousands.

Under the section, Description of Embodiments, it defines chemical nature of the possible subsitutions . The patent also includes various structural variations isomers, oligmers etc.